ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-CCP antibodies"

  • Abstract Number: 1010 • 2012 ACR/ARHP Annual Meeting

    Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies

    Stephanie Finzel1, Veronika Lang2, Arnd Kleyer1, Juergen Rech3, Bernhard Manger1, Elizabeth Araujo1, Axel J. Hueber4, Ulrike Harre5 and Georg Schett1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly…
  • Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting

    Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate

    Aase Haj Hensvold1, Saedis Saevarsdottir*2, Wanyiang Li*3, Vivianne Malmström4, Guy Cavet5, Lars Klareskog6 and Anca Catrina1, 1Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 2Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, 4Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5Crescendo Bioscience Inc., South San Francisco, CA, 6Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

    *equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
  • Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting

    14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients

    Walter P. Maksymowych1, Vivian P. Bykerk2, Désirée van der Heijde3, R. Landewe4 and Anthony Marotta5, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5Augurex Life Sciences Corp, North Vancouver, BC, Canada

    Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
  • Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting

    Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP

    Jose Felix Restrepo1, Inmaculada del Rincon1, Roy W. Haas2, Daniel F. Battafarano3 and Agustin Escalante2, 1Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX

    Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
  • Abstract Number: 973 • 2012 ACR/ARHP Annual Meeting

    New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis

    Diederik P.C. de Rooy1, Sacha Zhernakova1, Roula Tsonaka2, Fina Kurreeman3, René E.M. Toes1, Tom W. J. Huizinga4, Jeanine Houwing-Duistermaat5, Peter K. Gregersen6 and Annette H.M. van der Helm-van Mil1, 1Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Statistics, Statistics, Leiden University Medical Center, Leiden, Netherlands, 6Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients; approximately 54% of this variance is explained by genetic factors. Many…
  • Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting

    The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis

    Mehret Birru Talabi1, Rachel Mackey2, Larry W. Moreland3, Jan Dorman4, Kevin D. Deane5, Jeremy Sokolove6, V. Michael Holers7, William H. Robinson8, Brian Wallitt9 and Lewis Kuller10, 1Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, 5Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 6Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 8Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 9Washington Hospital Center, Baltimore, MD, 10Epidemiology, University of Pittsburgh, Pittsburgh, PA

    Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…
  • Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting

    Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis

    Youngkyun Kim1, Su-Jin Moon2, Hyoju Yi2 and Ji Hyeon Ju3, 11Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, 2Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA

    Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…
  • Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting

    Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study

    Saedis Saevarsdottir1, Marie Holmqvist2, Johan Askling3, Lars Alfredsson4 and Lars Klareskog5, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, 4Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
  • Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting

    Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis

    Heidi Kokkonen1, Mikael Brink2, Monika Hansson3, Linda Mathsson4, Ewa Lassen5, Per Johan Jakobsson6, Rikard Holmdahl7, Johan Rönnelid4, Lars Klareskog8 and Solbritt M. Rantapaa-Dahlqvist9, 1Rheumatology, Umeå University, Umea, Sweden, 2Umea University, Umea, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 5Transfusional Medicin, Umeå University, Umeå, Sweden, 6Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 7Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 8Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 9Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden

    Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
  • Abstract Number: 1769 • 2012 ACR/ARHP Annual Meeting

    Affinity Purification and Characterisation of Anti-CCP Antibodies From Plasma and Synovial Fluids of Patients with Rheumatoid Arthritis

    Elena Ossipova1, Catia Cerqueira2, Evan Reed2, Nastya Kharlamova2, Lena Israelsson2, Rikard Holmdahl3, Anca Catrina2, Vivianne Malmström2, Yngve Sommarin4, Lars Klareskog2, Per Johan Jakobsson2 and Karin Lundberg2, 1Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 4Euro-Diagnostica AB, Malmö, Sweden

    Background/Purpose: Autoimmunity in rheumatoid arthritis (RA) is characterized by autoantibodies to citrullinated proteins/peptides (ACPA). These antibodies (present in 60-70% of patients) antedate clinical onset and…
  • Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting

    Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis

    Lisbeth Arlestig1, Mikael Brink2, Monika Hansson3, Per Johan Jakobsson4, Rikard Holmdahl5, Linda Mathsson6, Johan Ronnelid6, Lars Klareskog7 and Solbritt M. Rantapaa-Dahlqvist8, 1Rheumatology, Umeå University, Umea, Sweden, 2Umea University, Umea, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 6Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, 7Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 8Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden

    Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…
  • Abstract Number: 1770 • 2012 ACR/ARHP Annual Meeting

    Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the “AMC-Senshu” Method

    Jing Shi1, George Janssen2, Peter van Veelen2, Janwouter Drijfhout2, Antony Cerami3, Tom Huizinga4, Leendert A. Trouw5 and René E.M. Toes4, 1Rheumatology, LUMC, Leiden, Netherlands, 2Immunohematology and Bloodbank, LUMC, Leiden, Netherlands, 3Nephrology, LUMC, Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and prognosis of Rheumatoid Arthritis (RA). The Anti-Modified Citrulline (AMC) (‘Senshu’) method is…
  • Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting

    Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis

    K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, A.A. Schouffoer2, T.H.E. Molenaar3, J.B. Harbers4, C. Bijkerk5, I. Speyer6, M. de Buck7, P.B. de Sonnaville8, B.A. Grillet9, Tom Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
  • Abstract Number: 1771 • 2012 ACR/ARHP Annual Meeting

    Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis

    Jing Shi1, Lotte van de Stadt2, Nivine Levarht3, T.W.J. Huizinga4, R. E. M. Toes4, Leendert A. Trouw5 and Dirkjan van Schaardenburg2, 1Rheumatology, LUMC, Leiden, Netherlands, 2Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: Recently, we discovered a new autoantibody system in rheumatoid arthritis (RA): anti carbamylated protein antibodies (anti-CarP).  These antibodies have additional prognostic value in predicting…
  • Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting

    Antibodies to Citrullinated Peptides in Tuberculosis

    Isabella Lima1, Rodrigo Oliveira2, Ajax Atta2, Samyra Marchi3, Lúcio Barbosa3, Eliana Reis3, Mitermayer G. Reis3 and Mittermayer Santiago4, 1Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, 2Universidade Federal da Bahia, Salvador, Brazil, 3Fundação Oswaldo Cruz, Salvador, Brazil, 4Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology